flurizan

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

How to Lose $100 Million in 40 Days

The failure of Myriad Genetics' experimental Alzheimer's drug Flurizan is surely unfortunate news for those with the disease and their families, but it also reflects badly on the Danish pharma H. Lundbeck, which paid Myriad $100 million on May 22 for European rights to the drug. Since Myriad has discontinued...

Tags: Alzheimer's Disease, Flurizan, David P. Hamilton

Blog posts 2008-07-01

Additional Resources

Myriad Genetics, Inc. F3Q08 (Qtr. End 03/31/08) Earnings Call Transcript

Question-and-Answer SessionThank you. [Operator Instructions]. Our first question comes from the line of [inaudible]. Please proceed. Unidentified Analyst Hi, it was noted that with the Flurizan Phase III data that excellent progress is being made on unblind [ph] data and it was unscheduled to report top line results, I...

Tags: Myriad Genetics Inc.

Earnings calls 2008-05-06

Myriad Genetics, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript

Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question is coming from the line Jeff Meacham from JP Morgan. Please proceed. Jeff Meacham - JP Morgan Hi, guys. Can you hear me? Peter Meldrum Yes. Adrian Hobden Yes. Jeff Meacham - JP Morgan Okay. Thanks for taking the...

Tags: Myriad Genetics Inc.

Earnings calls 2008-08-19

Wyeth, Elan and Bapineuzumab -- How to Lie With (Drug) Statistics

In what is becoming a sadly common ritual, Wyeth and Elan are pressing forward with an expensive, large-scale "phase III" trial of a risky drug based on wishful thinking and shoddy statistical analysis. The drug in question is bapineuzumab, a monoclonal antibody intended to treat Alzheimer's disease...

Tags: Alzheimer's Disease, Wyeth, Patient, Elan, David P. Hamilton

Blog posts 2008-07-29

Myriad exclusive licensee of a Mayo Clinic patent

Salt Lake-based Myriad Genetics Inc. said Wednesday it is the exclusive licensee of a new Mayo Clinic patent that covers a class of compounds to lower the levels of the toxic peptide amyloid beta 42. The peptide is thought to be an initiator of Alzheimer's disease. ...

Tags: Mayo Clinic, patent

Research articles 2005-06-30